Playphysio C.I.C. develops gamified respiratory physiotherapy technology for children and young people with cystic fibrosis and other long-term lung conditions. The company exists to help families complete their daily airway-clearance treatment, and to do it well. Its asset locked beneficiary is the Cystic Fibrosis Trust. During the year to 31 January 2026 the company remained in its pre-commercial research and development phase. It made no sales, and its activities were directed at completing the clinical evidence for the Playphysio system, preparing the regulatory route to market, and supporting the families already using the technology. The most significant outcome of the year was the completion of the analysis of our NIHR-funded feasibility randomised controlled trial with Alder Hey Children's Hospital. Statistical analysis was concluded with the University of Liverpool during the year, and a manuscript, "Making Physiotherapy Fun with Playphysio: A Feasibility Randomised Clinical Trial", was drafted in November 2025 with clinical and academic co-authors from Alder Hey, the University of Liverpool and Warwick Clinical Trials Unit. The trial recruited 59 children, 98 per cent of its target. Children using Playphysio completed significantly more airway-clearance treatments, and performed them to a significantly higher quality, than children receiving standard care. A conference abstract was also prepared for the European Cystic Fibrosis Conference. These results are the clinical evidence the company needs to bring its technology to more children, and they are the foundation for everything that follows. Throughout the year the company continued to provide its treatment-monitoring service, without charge, to the families who took part in the trial, so that no child lost access to the technology when the research ended. In January 2026 the company began the orderly return of study equipment, sending each family prepaid packaging and a letter of thanks. A new strand of community benefit opened during the year through contact with a family whose child has bronchiectasis and uses positive expiratory pressure (PEP) therapy. This extends the company's mission beyond cystic fibrosis to many more children who depend on daily airway clearance. The company also invested in the regulatory and quality groundwork needed to place devices on the UK market: a technical file structure and classification strategy under the UK and EU medical device regulations, a document-control convention, and templates for clinical evaluation in hospital and home settings. In November 2025 the company adopted an equity, inclusion, diversity and belonging policy. To make this work sustainable, the company sought funding and expert support. It took part in the Innovate UK Business Growth programme, including the Design for Growth cohort in spring 2025, and worked with its Innovate UK account manager to produce a commercialisation action plan in July 2025. Will Jackson, the company's founder and himself a cystic fibrosis parent, was selected for the EIT Health Patient Innovation Bootcamp, a European acceleration programme for patient and carer innovators run by Nova School of Business and Economics in Lisbon, IESE Business School in Barcelona and Copenhagen Business School. The programme combined in-person sessions in Lisbon and Copenhagen with online sessions from Barcelona, and gave the company an intensive induction into the medical, regulatory and business aspects of bringing a patient-led innovation to European health systems. Playphysio won the demo day pitch event that closed the bootcamp, and the prize was a place at the EIT Health finals in Paris. The company also applied to several other accelerator and grant programmes. In December 2025 it applied to the Joseph Levy Foundation, a charity with long standing ties to the cystic fibrosis community, and on 21 January 2026 the Foundation agreed an unrestricted grant of £25,000 to the company, to be applied to its social purposes from April 2026. The grant supports the company's plan to supply its physioPal devices to cystic fibrosis families

Playphysio's stakeholders are the children and families who use its technology or took part in research with it; the clinical teams who care for them, in particular the respiratory and physiotherapy teams at Alder Hey Children's Hospital; its research partners at the University of Liverpool and Warwick Clinical Trials Unit; the Cystic Fibrosis Trust, as asset-locked beneficiary, and the wider cystic fibrosis charity community, including the Joseph Levy Foundation; the NHS bodies whose adoption and procurement pathways the company must meet; and the funders and advisers who support the company, including Innovate UK Business Growth. Trial families were consulted through the trial's participant satisfaction questionnaire, analysed in November 2025, and through direct correspondence. In response the company kept its monitoring service running for them after the trial closed and managed the return of equipment so that families were not left to arrange it themselves. Clinical and academic partners at Alder Hey, the University of Liverpool and Warwick were consulted throughout the statistical analysis and the drafting of the trial manuscript. Their feedback shaped how the outcomes are reported and the company's plans for a wider evaluation of the technology in NHS settings. A family living with bronchiectasis, and with their consent their child's hospital respiratory team, were interviewed about the daily reality of PEP therapy at home. Their feedback became the recorded user needs for the digital manometer design, and the company responded by starting that design rather than assuming the needs of this group matched those of cystic fibrosis families. Innovate UK Business Growth advisers reviewed the company's strategy and produced a written action plan. The company responded by prioritising regulatory readiness and clinical evidence over premature commercial activity. An independent brand adviser reviewed how the company explains itself to parents and clinicians, and the company revised its key messages and website content in response. The Joseph Levy Foundation was consulted in person at its 60th anniversary event in London and through the application process. The agreed grant and the plan behind it reflect that dialogue.

No remuneration was received

No transfer of assets other than for full consideration